 Arix Bioscience PLC LON:ARIX said portfolio company LogicBio Therapeutics, Inc. NASDAQ:LOGC has signed a strategic collaboration with CANbridge Pharmaceuticals as well as a research partnership with Daiichi Sankyo. Under the terms of the agreement with CANbridge Pharmaceuticals, LogicBio is eligible to receive an upfront payment of US10mln in addition to up to US581mln in option payments and milestones, plus up to double-digit royalties. 